PharmExec Blog

Europe Approves First Medicine for Castleman's Disease

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for Sylvant (siltuximab) for adult patients with multicentric Castleman’s disease.

Castleman’s disease is a rare disorder characterized by non-cancerous growth of the lymph nodes and related tissues. There are currently no medicinal products authorized in the European Union for its treatment.

Janssen-Cilag’s Sylvant, shown in clinical trials to reduce tumor burden and improve disease symptoms, was developed using incentives put in place by Europe’s orphan legislation. It was designated as an orphan medicine in 2007; at that time it was estimated that Castleman’s disease affected less than 1 in 10,000 people in the EU.



This entry was posted in Europe, Global, Orphan Drugs, Regulatory and tagged , , , . Bookmark the permalink. Trackbacks are closed, but you can post a comment.


  1. Posted March 21, 2014 at 12:46 pm | Permalink

    I would like to know about the best treatment for Castleman’s disease with fully cure from this disease if you have any center which I can continue my treatment please send to my thier address
    and the cost including accommodation and how long it need to stay there.

    Best regards,

  2. Steven Hendricks
    Posted April 13, 2014 at 11:29 pm | Permalink


    recommend you post your question to the global CD community launched last week on RareConnect. Google RareConnect and you’ll see the link for the CD forum. The moderators of the forum will be able to recommend a center based on where you live.

Post a Comment

Your email is never published nor shared. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

  • Categories

  • Meta